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For most expression studies focusing on the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, sensitive and
specific antibodies (Abs) are critically needed. Several Abs have been produced commercially or by research laboratories for CFTR detection
in both cell lines with heterologous or endogenous expression and native cells/tissues. Here, we review the applicability of most Abs
currently in use in CF research for the biochemical and/or immunocytochemical detection of CFTR.
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1. Introduction and (5) type and quality of secondary reagents whenThere are a variety of factors that influence the
success of an immunochemical technique. According to
some authors, these include (1) the avidity of the Ab
for the antigen (Ag), (2) the concentration of the Ab
and its specificity for the Ag, (3) possible alteration of
the Ag epitope during the experimental procedure, (4)
accessibility of the Ab to the Ag during the technique,1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.016
Abbreviations: Ab, antibody; Ag, antigen; ELISA, enzyme-linked
immunosorbent assay.
* Corresponding author. Department of Chemistry and Biochemistry,
University of Lisbon, Lisboa, Portugal. Tel.: +351-21-751-64-40/+351-21-
750-08-61; fax: +351-21-752-64-10/+351-21-750-00-88.
E-mail address: mdamaral@fc.ul.pt (M.D. Amaral).used [1].
When CFTR is being detected, at least two additional
factors should be considered, namely, the polarity status
of cells under analysis and the levels of CFTR endoge-
nous expression in cells or tissues, or copy number of
transgene, in case of transfected cell lines [2].
Here, we review most Abs currently in use in CF
research both polyclonal and monoclonal from commer-
cial sources or produced by research laboratories, and
summarize their applicability for the biochemical and/or
immunocytochemical detection of CFTR, based on several
comparative studies previously published [2–7]. Usage of
anti-CFTR Abs described here includes detection in
different types of samples, namely, (1) heterologous
expression systems, (2) cell lines constitutively synthesiz-
ing the protein, and (3) native tissues.ed by Elsevier B.V. All rights reserved.
Table 1
Review of anti-CFTR antibodies applicability
Antibody Typea Epitope Source Applicabilityb Specificity Referencesc
Cell lines Native tissue ells
WB IP ICC I C
N-term-Birmd PC N-term (2–79) D Cyr
(Birmingham, AL, USA)
ND T (+++) ND N H [13]
MM13-4 MC (IgG1) N-term (25–35) Chemicon
(Temecula, CA, USA)
T (+++)/E (+) T (+++)/E (+) N (+/ ) N H [14]
MA1-935 MC (IgM) 1st EL (103-117) Affinity Bioreagents
(Golden, CO, USA)
ND ND ND N H, M [15,16]
PA1-935 PC (IgM) 1st EL (103-117) Affinity Bioreagents ND ND ND N H [15,16]
MATG 1031 MC (IgG1) 1st EL (107-117) Transge`ne
(Strasbourg, France)
ND ND ND S ( ) H [17]
L12B4 MC (IgG2a) Pre-NBD (386–412) Chemicon T (+++)/E (+) T (+++)/E ( ) N (+/ ) N H, M, Ra [14]
181 PC Pre-NBD (415–427) W Guggino
(Baltimore, MD, USA)
Unsp ND ND N H [18,19]
MATG 1061 MC (IgG2a) NBD1 (503–507/509–515) Transge`ne ND ND N (+++) A (+++)/I (++)/SG (+) H [17,20]
NBD1-Birm PC NBD1-R D Cyr T (+++)/E (+) T (+++)/E (+) ND N H [2]
13-1 MC (IgG1) R (590–830) R&D Systemse
(Abrington, UK)
ND ND N (+/ ) A ( )/I (++) H [21,22]
G449 PC R (653–716) H De Jonge T (++)/E (+) T (++)/E (+) N (+++)f I ++) H [23,24]
CC24-R PC R (693–716) H De Jonge T (+++)/E (++) T (+)/E ( ) N (++) A ( )/I/SG (++) H [23]
MATG 1104 MC (IgG1) R (722–734) Transge`ne T (+++)/E (+/ ) T ( )/E ( ) N (++)g A (++)/I (++)/SG (++) H [3,25]
169 PC R (724–746) W Guggino ND T (+++)/E (+) N (++) A ( ) H [18,19]
M3A7 MC (IgG1) NBD2-C-term (1197–1480) Chemicon T (+++)/E (+) T (+++)/E (++) N (+/ ) A (+/ )/I (+/ )/SG (++) H, M, Ra [3,14]
24-1 MC (IgG2a) end NBD2-C-term (1377–1480) R & D Systemse T (+++)/E (++) T (+++)/E (++) N (+++) A (++)/I (+/ ) H [26–28]
GA-1 MC end NBD2-C-term (1382–1480) K Kirk
(Birmingham, AL, USA)
_ T (+++)/E (+/ ) ND N H [29,30]
C1468 PC C-term (1468–1480) R Kopito
(Stanford, CA, USA)
_ T ( )/E (ND) ND N H [31,32]
Lis-1 PC C-term (1468–1480) MD Amaral T (+++) T (+++) N (+++) N H, M [2,7]
R3195 PC C-term (1468–1480) C Marino
(Memphis, TN, USA)
T (+++)/E (+) T (+++) ND I ++) H, M, Ra [33–35]
MP-CT1 PC C-term R Dormer T (+++)/E (++) T (+++)/E (++) N (+++) A (++), I (++) H, M [36–38]
a Polyclonal (PC); monoclonal (MC).
b Based in Refs. [2–7]. For further details, please refer to original articles. Scale is from (+++) good detection, (++) reasonable detection, (+) poor d tection, ( ) no detection to unspecific (Unsp) or not
determined (ND).
c Original reference, when applicable, in boldface.
d Abbreviations: C-terminus (C-term), extracellular loop (EL), Regulatory domain (R), nucleotide binding domain (NBD), N-terminus (N-t ), Western blot (WB), immunoprecipitation (IP),
immunocytochemistry (ICC), immunohistochemistry (IHC), endogenous (E), transfected (T), nasal (N), airways (A), intestine (I), sweat gland (SG), hum n (H), rat (Ra), mouse (M).
e These Abs were formerly available from Genzyme.
f H. Davidson and H. De Jonge, unpublished results.
g D. Penque and H. Davidson, unpublished results.
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2.1. Antibodies
All anti-CFTR Abs described here, as well as their
original sources and/or references are presented in Table 1.
2.2. Affinity purification
The affinity purification of the antiserum usually
improves the performance of an Ab. A good protocol can
be found at the European Working Group on CFTR Ex-
pression website [8]. An alternative protocol is described
elsewhere [2]. Briefly, antisera purification involves cou-
pling of the epitope peptide to activated Sepharose beads,
which are then used to fill up a column. The CFTR
antiserum is then passed through this column and acid-
eluted in 0.5-ml fractions, followed by a neutralization step.
An additional step for desalting and concentration can be
performed in columns designed for this purpose, with
10,000 MW cutoff limits [2]. The eluate fractions should
then be assessed for efficiency in detecting the CFTR
peptide epitope [e.g., on enzyme-linked immunosorbent
assay (ELISA) plates] or CFTR directly (e.g., by Western
blot). Affinity-purified Ab can be stored at 4 jC in the
presence of sodium azide.
2.3. Immunodetection techniques
Consensus protocols for immunodetection of CFTR are
described elsewhere in this supplement. Biochemical de-
tection techniques (namely Western blot and [35S]-label-
ling followed by immunoprecipitation of CFTR) are
described by Farinha et al. [9]. Detection of CFTR protein
by [32P]-phosphorylation assays is described elsewhere
[10]. The detection of CFTR by immunocytochemistry
in native cells is described by Harris et al. [11] and by
immunohistochemistry in tissues elsewhere [12].3. Conclusion
CFTR protein is difficult to study and analysis based on
detection of its presence is critically dependent on the use of
robust Abs. We provide here a review of most anti-CFTR
Abs available either from commercial or research sources
that evidenced good results for the detection of wt- and
F508del-CFTR by at least one immunochemical technique.
The end-user researcher can thus save time and effort by
choosing the Ab that best applies to the desired purpose.Acknowledgements
European Thematic Network around Cystic Fibrosis and
Related Diseases (EU-QLK3-CT-1999-00241).References
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